Logo image of PVLA

PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

USA - NASDAQ:PVLA - US6979471090 - Common Stock

62.69 USD
+0.44 (+0.71%)
Last: 9/30/2025, 8:00:01 PM
62.69 USD
0 (0%)
After Hours: 9/30/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, PVLA scores 3 out of 10 in our fundamental rating. PVLA was compared to 536 industry peers in the Biotechnology industry. While PVLA has a great health rating, there are worries on its profitability. PVLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PVLA had negative earnings in the past year.
In the past year PVLA has reported a negative cash flow from operations.
PVLA had negative earnings in each of the past 5 years.
In the past 5 years PVLA always reported negative operating cash flow.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

PVLA's Return On Assets of -27.07% is fine compared to the rest of the industry. PVLA outperforms 70.71% of its industry peers.
With a decent Return On Equity value of -38.70%, PVLA is doing good in the industry, outperforming 72.57% of the companies in the same industry.
Industry RankSector Rank
ROA -27.07%
ROE -38.7%
ROIC N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PVLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PVLA has more shares outstanding
Compared to 5 years ago, PVLA has more shares outstanding
PVLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 16.06 indicates that PVLA is not in any danger for bankruptcy at the moment.
PVLA's Altman-Z score of 16.06 is amongst the best of the industry. PVLA outperforms 90.11% of its industry peers.
PVLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.06
ROIC/WACCN/A
WACC10.03%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 8.84 indicates that PVLA has no problem at all paying its short term obligations.
PVLA's Current ratio of 8.84 is fine compared to the rest of the industry. PVLA outperforms 76.87% of its industry peers.
A Quick Ratio of 8.84 indicates that PVLA has no problem at all paying its short term obligations.
PVLA has a better Quick ratio (8.84) than 77.05% of its industry peers.
Industry RankSector Rank
Current Ratio 8.84
Quick Ratio 8.84
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

PVLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.99%, which is quite impressive.
The Revenue for PVLA has decreased by -17.56% in the past year. This is quite bad
Measured over the past years, PVLA shows a small growth in Revenue. The Revenue has been growing by 0.49% on average per year.
EPS 1Y (TTM)34.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-17.56%
Revenue growth 3Y-17.59%
Revenue growth 5Y0.49%
Sales Q2Q%N/A

3.2 Future

PVLA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.33% yearly.
The Revenue is expected to decrease by -23.34% on average over the next years. This is quite bad
EPS Next Y99.01%
EPS Next 2Y38.38%
EPS Next 3Y24%
EPS Next 5Y13.33%
Revenue Next Year20.37%
Revenue Next 2Y-97.65%
Revenue Next 3Y-25.99%
Revenue Next 5Y-23.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2027 10M 20M 30M 40M
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PVLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PVLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as PVLA's earnings are expected to grow with 24.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.38%
EPS Next 3Y24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PVLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (9/30/2025, 8:00:01 PM)

After market: 62.69 0 (0%)

62.69

+0.44 (+0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11
Inst Owners45.65%
Inst Owner Change15.33%
Ins Owners17.79%
Ins Owner Change0.59%
Market Cap693.35M
Analysts82.22
Price Target66.77 (6.51%)
Short Float %9.17%
Short Ratio4.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-136.67%
Min EPS beat(2)-313.44%
Max EPS beat(2)40.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.32%
PT rev (3m)32.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.78%
EPS NY rev (1m)-5.17%
EPS NY rev (3m)-23.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.48
P/tB 12.48
EV/EBITDA N/A
EPS(TTM)-36
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS5.03
TBVpS5.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.07%
ROE -38.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.84
Quick Ratio 8.84
Altman-Z 16.06
F-Score4
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y99.01%
EPS Next 2Y38.38%
EPS Next 3Y24%
EPS Next 5Y13.33%
Revenue 1Y (TTM)-17.56%
Revenue growth 3Y-17.59%
Revenue growth 5Y0.49%
Sales Q2Q%N/A
Revenue Next Year20.37%
Revenue Next 2Y-97.65%
Revenue Next 3Y-25.99%
Revenue Next 5Y-23.34%
EBIT growth 1Y-173.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-123.12%
EBIT Next 3Y-75.74%
EBIT Next 5YN/A
FCF growth 1Y78.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.02%
OCF growth 3YN/A
OCF growth 5YN/A